DYNAMICS OF THE STRUCTURALLY FUNCTIONAL STATE OF CAROTID ARTERIES IN MEN WITH HYPERTENSION WITH THERAPY WITH COMBINATIONS OF LORORTANE AND RAMPIRIL WITH INDAPAMIDE FOR SIX MONTHS OF TREATMENT DEPENDING ON THE LEVEL OF UREMIA AND THE FORM OF ARTERIAL HYPERTENSION
DOI:
https://doi.org/10.11603/1811-2471.2017.v0.i4.8365Keywords:
uric acid, hypertonic disease, carotid arteries, a combination of losartan and ramipril with indapamide.Abstract
The aim: to study the dynamics of the surgical and functional state of carotid arteries in men with hypertension with the treatment of combinations of losartan and ramipril with indapamide for six months of treatment, depending on the level of uremicemia and the form of arterial hypertension.
Materials and Methods. The groups of elderly and aged men with second stage of arterial hypertension and different levels of uremia were studied. The dynamics of the structural and functional state of carotid arteries in men with hypertension with the treatment of combinations of losartan and ramipril with indapamide for 6 months of treatment was studied.
Results and Discussion. The key ideology of our study was to increase the effectiveness of treating men with hypertension of stage II of the elderly on the basis of a study of the relationship between plasma uric acid (UA) and the structural and functional state of carotid arteries, vasoprotective efficacy of combinations of inhibitors ACE of ramipril and BRA ІІ losartan with indapamide, and determining their predictors efficiency. This concept provided a perspective for the development of differentiated antihypertensive treatment of patients with GC in the elderly and aged. 90 men from hypertension II stage of elderly and senile age (average age 72.5 years) and 28 healthy men of the same age (average age 70.9 years) without signs of significant cardiovascular disease were examined.
Conclusions The positive effect of combinations of losartan and ramipril with indapamide on the structural and functional state of carotid arteries (CA) in men with hypertension over 6 months of treatment has been shown. At the same time, in general, the group did not find the benefits of one or another variant of antihypertensive therapy for influencing the dynamics of indicators of the structural and functional state of CA. The effect of the combination of ramipril with indapamide on the structural and functional state of CA in men with hypertension over a period of 6 months does not reveal a statistically significant association with the initial level of UA and the form of hypertension. Instead, the use of the combination of losartan with indapamide reveals a statistically significant association with the level of UA and the form of hypertension characterized by a more significant decrease in TIM, VT CA, V CA and RI, and an increase in D CA and PI in patients with hyperuricemia and isolated systolic hypertension (ISH). The use of the combination of losartan with indapamide for 6 months in men with UA exhibits statistically significant advantages over the combination of indapamide with ramipril for influencing the structural and functional state of CA in patients with initial hyperuricaemia and ISH, which suggests a more convincing vasoprotective effect of the drug in these of patients.
References
Bilchenko, A.V. (2009). Giperurikemiya kak faktor riska serdechno-sosudistoy zabolevayemosti i smertnosti [Hyperuricemia as a risk factor for cardiovascular morbidity and mortality]. Zdorovia Ukrainy – Health Ukraine, 10 (1), 46-48 [in Russian].
Kovalenko, V.M., & Lutai, M.I. (Eds.) (2016). Sertsevo-sudynni zakhvoriuvannia: rekomendatsii z diahnostyky, profilaktyky ta likuvannia [Cardiovascular diseases: recommendations for diagnosis, prevention and treatment]. Kyiv: MORION [in Ukrainian].
Kolomoets, M.Yu., & Vasheniak, O.O. (2012). Komorbidnist ta polimorbidnist u terapevtychnii praktytsi [Comorbidity and polymorbidity in therapeutic practice]. Ukr. med. Chasopys – Ukrainian Medical Journal, 5 (91), 140-143 [in Ukrainian].
Chernyshov, V.A., & Bohun, L.V. (2008). Vzaiemozviazok porushen vuhlevodnoho ta purynovoho obminu z vyrazhenistiu oznak metabolichnoho syndromu u khvorykh na ishemichnu khvorobu sertsia [Interrelation of carbohydrate and purine metabolism disorders with the severity of signs of metabolic syndrome in patients with coronary heart disease]. Ukrainskyi terapevtychnyi zhurnal – Ukrainian Therapeutic Journal, 1 (17), 24-31 [in Ukrainian].
Shuba, N.M. (2013). Giperurikemiya – multimorbidnaya patologiya v revmatologii [Hyperuricemia is a multimorbid pathology in rheumatology]. Ukr. revmatol. Zhurn. – Ukr. Rheumatology. Journal, 2 (52), 14-22 [in Russian].
Hoieggen, A., Alderman, M.H., Kjeldsen, S.E., Julius, S., Devereux, R.B., De Faire, U. et al. (2004). The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int., 65 (3), 1041-1049.
Messerli, F.H., Frohlich, E.D., Dreslinski, G.R., Suarez, D.H., & Aristimuno, G.G. (1980). Serum uric acid in essential hypertension: an indicator of renal vascular involment. Ann. Intern. Med., 93 (6), 817-821.
Rosolowsky, E.T., Ficociello, L.H., Maselli, N.J., Niewczas, M.A., Binns, A.L., Roshan, B. et al. (2008). High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol., 3 (3), 706-713.
Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C., & Brunetti, P. (2000). Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension, 36 (6), 1072-1078.
Zhang, W., Doherty, M., Pascual, E., Bardin, T., Barskova, V., Conaghan, P. et al. (2006). EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann. Rheum. Dis., 65 (10), 1301-1311.
Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A. et al. (2010). 2010 ACC/AHA guidelines for assessment of cardiovascular risk in asymptomatic adults: executive summury: a reports of the American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. J. Amer. Coll. Cardiology, 56, 2182-2199.
